Solventum Corporation (SOLV) Gets a Buy from Stifel Nicolaus
In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Solventum Corporation, with a price target of $105.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Wise covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Masimo, and Medtronic. According to TipRanks, Wise has an average return of 0.9% and a 53.60% success rate on recommended stocks.
In addition to Stifel Nicolaus, Solventum Corporation also received a Buy from BTIG’s Ryan Zimmerman in a report issued on January 2. However, on January 5, Bank of America Securities maintained a Hold rating on Solventum Corporation (NYSE: SOLV).
Based on Solventum Corporation’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.1 billion and a net profit of $1.27 billion. In comparison, last year the company earned a revenue of $2.08 billion and had a net profit of $122 million
Read More on SOLV:
